"Captopril" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
Concept/Terms
Captopril- Captopril
- (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline
SQ-14,534- SQ-14,534
- SQ 14,534
- SQ14,534
- SQ-14534
- SQ 14534
- SQ14534
SQ-14,225- SQ-14,225
- SQ 14,225
- SQ14,225
- SQ-14225
- SQ 14225
- SQ14225
Below are MeSH descriptors whose meaning is more general than "Captopril".
Below are MeSH descriptors whose meaning is more specific than "Captopril".
This graph shows the total number of publications written about "Captopril" by people in Harvard Catalyst Profiles by year, and whether "Captopril" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 4 | 2 | 6 |
| 1995 | 3 | 4 | 7 |
| 1996 | 0 | 2 | 2 |
| 1997 | 3 | 3 | 6 |
| 1998 | 2 | 2 | 4 |
| 1999 | 4 | 0 | 4 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 5 | 6 |
| 2002 | 0 | 2 | 2 |
| 2003 | 3 | 3 | 6 |
| 2004 | 4 | 3 | 7 |
| 2005 | 3 | 4 | 7 |
| 2006 | 3 | 3 | 6 |
| 2007 | 1 | 6 | 7 |
| 2008 | 1 | 4 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 1 | 4 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
Below are the most recent publications written about "Captopril" by people in Profiles.
-
The role of confirmatory tests in the diagnosis of primary aldosteronism. J Formos Med Assoc. 2024 Mar; 123 Suppl 2:S104-S113.
-
Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. JCI Insight. 2022 07 08; 7(13).
-
Hydrogen Sulphide Release via the Angiotensin Converting Enzyme Inhibitor Zofenopril Prevents Intimal Hyperplasia in Human Vein Segments and in a Mouse Model of Carotid Artery Stenosis. Eur J Vasc Endovasc Surg. 2022 02; 63(2):336-346.
-
Reduction of pTau and APP levels in mammalian brain after low-dose radiation. Sci Rep. 2021 01 26; 11(1):2215.
-
Plasma Aldosterone After Seated Saline Infusion Test Outperforms Captopril Test at Predicting Clinical Outcomes After Adrenalectomy for Primary Aldosteronism. Am J Hypertens. 2019 10 16; 32(11):1066-1074.
-
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. J Cancer Res Clin Oncol. 2019 Jun; 145(6):1495-1507.
-
Renal artery stenting for atherosclerotic renal artery stenosis identified in patients with coronary artery disease: Does captopril renal scintigraphy predict outcomes? J Clin Hypertens (Greenwich). 2018 02; 20(2):373-381.
-
The effect of vitamin D on renin-angiotensin system activation and blood pressure: a randomized control trial. J Hypertens. 2017 04; 35(4):822-829.
-
Structural Basis of Metallo-ß-Lactamase Inhibition by Captopril Stereoisomers. Antimicrob Agents Chemother. 2016 01; 60(1):142-50.
-
Inhibition of the dapE-Encoded N-Succinyl-L,L-diaminopimelic Acid Desuccinylase from Neisseria meningitidis by L-Captopril. Biochemistry. 2015 Aug 11; 54(31):4834-44.